Professor Luis Villegas, a faculty member at the Universidad Nacional Experimental Francisco de Miranda (UNEFM), requires immediate financial assistance to procure critical oncology medication following a diagnosis of prostate adenocarcinoma with bone metastasis. The treatment, which has been delayed for two months, is essential to stabilize ten identified skeletal lesions.
Clinical Essentials for Metastatic Prostate Cancer
- Bone Metastasis Management: Metastatic prostate cancer affecting the skeletal structure requires systemic therapy to prevent pathological fractures and manage pain, often involving bone-modifying agents or targeted hormone therapy.
- Treatment Continuity: Interrupting oncology protocols, such as the two-month delay reported by Notiprensa Digital, significantly increases the risk of disease progression and skeletal-related events.
- Systemic Impact: The involvement of the pelvis, shoulder, and multiple vertebral segments (L1, L3, L4, L5 and D9-D12) necessitates urgent pharmacological intervention to maintain structural integrity and quality of life.
Skeletal Metastasis and the Need for Urgent Pharmacological Access
Following a surgical procedure for prostate adenocarcinoma last year, Professor Luis Villegas received a diagnosis of bone metastasis this October. The pathology, which has spread to ten distinct locations including the pelvis, the left shoulder, and the lumbar and dorsal regions of the spine, requires a high-priority injection that currently remains inaccessible through the patient’s institutional insurance coverage.
Notiprensa Digital reported that the cost of this single, critical dose is approximately 400,000 bolívares. Because the institutional supply chain through his medical insurance has failed to provide the necessary medication for two consecutive months, the professor’s clinical stability is now at risk. The university community and family members are seeking urgent financial contributions or logistical support to locate and acquire the medication within the national market.
Clinical Data on Advanced Prostate Cancer Management
Prostate cancer that migrates to the bone often utilizes the RANK/RANKL signaling pathway, where tumor cells stimulate osteoclasts—cells responsible for bone resorption—leading to weakened bone density. Clinical protocols often utilize bisphosphonates or RANK ligand inhibitors to mitigate these structural risks.
| Clinical Factor | Impact on Patient Status |
|---|---|
| Metastatic Sites | 10 distinct lesions (Pelvis, Shoulder, Vertebrae L1, L3, L4, L5, D9-D12) |
| Estimated Cost | ~400,000 bolívares per injection |
Seek Emergency Medical Care for Severe Symptoms
If a patient experiences sudden, severe focal bone pain, neurological deficits, or numbness in the extremities, they must seek immediate emergency medical evaluation, as these may indicate impending spinal cord compression or pathological fracture.
Support Channels for the Professor
To facilitate the acquisition of this treatment, specific channels have been provided for those able to assist. Financial contributions can be directed to the Banco de Venezuela account associated with identification number 4.068.678. For logistical information regarding the availability of the medication in the national market, the contact number 04122672872 is currently serving as the primary point of communication for this health emergency.
References
Disclaimer: This report is for informational purposes based on the emergency request filed by the patient’s community and does not constitute individual medical advice. Always consult with an oncologist or primary care physician regarding specific treatment protocols and the management of metastatic disease.
